Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Cushing Syndrome II: Pathophysiology

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment of adult patients with acute lymphoblastic leukemia in the Czech Republic in the period 2007-2020.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2023

Same author

Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2019

Same author

Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16μg/kg/day: efficacy and safety.

Neoplasma·2015

Same author

[Invasive aspergillosis in hematooncological patients: advantages and disadvantages of various diagnostic methods, treatment options and financial costs of therapy].

Vnitrni lekarstvi·2013

Same author

[Treatment of adult acute lymphoblastic leukemia according to GMALL 07/2003 study protocol in the Czech Republic - the first experience].

Vnitrni lekarstvi·2010

Same author

Structure of nanocrystalline anatase solved and refined from electron powder data.

Acta crystallographica. Section A, Foundations of crystallography·2002

Search research articles

Related Experiment Video

Updated: May 4, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

[Histiocytic sarcoma].

E Létalová, M Moulis, M Klincová

Vnitrni Lekarstvi

|December 20, 2013

Summary

This summary is machine-generated.

Histiocytic sarcoma (HS) is a rare cancer originating from histiocytes. Treatment outcomes for HS patients vary significantly based on the disease stage at diagnosis.

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Experiment Videos

Last Updated: May 4, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Area of Science:

Oncology
Hematology
Pathology

Background:

Histiocytic sarcoma (HS) is an exceptionally rare malignancy originating from histiocytes.
Histiocytic neoplasms account for less than 1% of all lymphoid and soft tissue malignancies.
The precise incidence of histiocytic sarcoma remains undescribed.

Observation:

This report details three patients diagnosed with histiocytic sarcoma.
All patients received treatment at the Department of Internal Medicine, Hematology, and Oncology, Faculty Hospital Brno.
Despite sharing the same diagnosis, patient responses to treatment varied.

Findings:

Treatment efficacy in histiocytic sarcoma is strongly influenced by the stage of the disease at the time of diagnosis.
Varied treatment responses were observed among the three HS patients presented.
Early diagnosis may correlate with improved treatment outcomes.

Implications:

Understanding the impact of disease stage is crucial for tailoring histiocytic sarcoma treatment strategies.
Further research is needed to elucidate the prognostic factors in histiocytic sarcoma.
This case series highlights the heterogeneity of treatment responses in rare histiocytic malignancies.